Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

Bertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa et al. · Science · 2017 · 5.4K citations

Life Sciences, Immunology, Oncology +17

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Joaquim Bellmunt, Ronald de Wit, David J. Vaughn et al. · New England Journal of Medicine · 2017 · 3.4K citations · Full text

Medicine, Oncology, Pharmacology +17

RECIST 1.1—Update and clarification: From the RECIST committee

Lawrence H. Schwartz, Saskia Litière, Elisabeth G.E. de Vries et al. · European Journal of Cancer · 2016 · 1.9K citations

Agriculture, Public Policy, Separation Of Powers +3

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

Padmanee Sharma, Margitta Retz, Arlene O. Siefker‐Radtke et al. · The Lancet Oncology · 2017 · 1.7K citations

Medicine, Oncology, Urology +12

Proton pump inhibitors affect the gut microbiome

Floris Imhann, Marc Jan Bonder, Arnau Vich Vila et al. · Gut · 2015 · 1.3K citations · Full text

Life Sciences, Microbiology, Pharmacology +15